Planetary Technologies

Bioeconomy Fund 1, established in 2015 and managed by Bioeconomy Capital in Seattle, Washington, focuses on early-stage investments in the bioeconomy sector. The fund aims to accelerate advancements in biotechnology by leveraging the extensive operational and product development experience of its management team, which encompasses over fifty years of expertise in synthetic biology and related engineering fields. Bioeconomy Capital employs a unique investment strategy that emphasizes the creation and deployment of technological capabilities essential for the 21st-century economy. The fund has previously invested in notable companies, including Zymergen, Riffyn, Synthace, RoosterBio, Arzeda, Bellwether Bio, EdenWorks, and Lumen Biosciences, reflecting its commitment to fostering innovation across various industries, including software, pharmaceuticals, biotechnology, and chemicals.

Rob Carlson

Managing Director and Co-Founder

Rik Wehbring

Managing Director

Past deals in Seattle, WA

Arzeda

Series B in 2022
Arzeda Corporation, founded in 2008 and based in Seattle, Washington, specializes in the development and commercialization of innovative enzymes and specialty chemical products. The company leverages advanced computational enzyme design technology to create designer proteins and enzymes tailored for diverse applications in polymers, pharmaceuticals, and industrial chemicals. By focusing on biocatalysis, Arzeda aims to provide clients with high-performance, cost-effective, and sustainable solutions that enhance their products. The company's expertise in synthetic biology positions it as a leader in the field, enabling the development of a robust portfolio that addresses the growing demand for advanced chemical products.

Parse Biosciences

Series B in 2022
Parse Biosciences, based in Seattle, Washington, focuses on single-cell analysis and was incorporated in 2018. The company is dedicated to developing innovative technologies that enhance the understanding of cellular diversity and function at the single-cell level. By leveraging advanced methodologies, Parse Biosciences aims to provide researchers with powerful tools for exploring complex biological systems, ultimately advancing the fields of genomics and biomedical research.

Parse Biosciences

Series A in 2021
Parse Biosciences, based in Seattle, Washington, focuses on single-cell analysis and was incorporated in 2018. The company is dedicated to developing innovative technologies that enhance the understanding of cellular diversity and function at the single-cell level. By leveraging advanced methodologies, Parse Biosciences aims to provide researchers with powerful tools for exploring complex biological systems, ultimately advancing the fields of genomics and biomedical research.

Lumen Bioscience

Series B in 2020
Lumen Bioscience, Inc. is a biotechnology company focused on developing therapeutic biologics for oral delivery. It utilizes Spirulina, a blue-green algae, as an industrial-scale production platform for high-value molecules. The company engages in various services, including synthetic biology, protein design, immunology, bioreactor engineering, and cell physiology, catering to the food, cosmetics, and healthcare industries. Founded in 2017 and based in Seattle, Washington, Lumen Bioscience is advancing the development of topically and mucosally delivered biologic drugs aimed at treating and preventing common diseases.

Lumen Bioscience

Series A in 2017
Lumen Bioscience, Inc. is a biotechnology company focused on developing therapeutic biologics for oral delivery. It utilizes Spirulina, a blue-green algae, as an industrial-scale production platform for high-value molecules. The company engages in various services, including synthetic biology, protein design, immunology, bioreactor engineering, and cell physiology, catering to the food, cosmetics, and healthcare industries. Founded in 2017 and based in Seattle, Washington, Lumen Bioscience is advancing the development of topically and mucosally delivered biologic drugs aimed at treating and preventing common diseases.

Arzeda

Series A in 2017
Arzeda Corporation, founded in 2008 and based in Seattle, Washington, specializes in the development and commercialization of innovative enzymes and specialty chemical products. The company leverages advanced computational enzyme design technology to create designer proteins and enzymes tailored for diverse applications in polymers, pharmaceuticals, and industrial chemicals. By focusing on biocatalysis, Arzeda aims to provide clients with high-performance, cost-effective, and sustainable solutions that enhance their products. The company's expertise in synthetic biology positions it as a leader in the field, enabling the development of a robust portfolio that addresses the growing demand for advanced chemical products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.